Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial

J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.

Authors

Elena Peeva¹, Emma Guttman-Yassky², Anindita Banerjee³, Rodney Sinclair⁴, Lori Ann Cox⁵, Linda Zhu³, Hua Zhu⁶, Michael Vincent³, Brett King⁷

Affiliations

¹ Pfizer, Cambridge, Massachusetts. Electronic address: [email protected].
² Icahn School of Medicine at Mt. Sinai, New York, New York.
³ Pfizer, Cambridge, Massachusetts.
⁴ Sinclair Dermatology, Melbourne, Victoria, Australia.
⁵ Pfizer, Basking Ridge, New Jersey.
⁶ Pfizer, Shanghai, China.
⁷ Yale University School of Medicine, New Haven, Connecticut.

PMID: 34915057
DOI: 10.1016/j.jaad.2021.12.008

No abstract available

Publication types

Clinical Trial, Phase II
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

MeSH terms

Alopecia Areata* / drug therapy
Humans
Janus Kinase Inhibitors* / therapeutic use
Single-Blind Method

Substances

Janus Kinase Inhibitors

Supplementary concepts

Diffuse alopecia

Associated data

ClinicalTrials.gov/NCT02974868